The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Copyright 2025 The Associated Press. All Rights Reserved. Leverkusen’s head coach Xabi Alonso looks on ahead of the German Bundesliga soccer match between Borussia ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are no longer used in US homes ...

Trial was the latest over harm tied to school outside Seattle Company vows appeal of verdict and ‘excessive’ damages awarded Bayer AG was told by a jury to pay $100 million to four people at a Seattle ...

Jury Rules Bayer (Monsanto) Must Pay $100M in Trial Over PCBs in Washington School. Bayer has been ordered to pay $100 million to four individuals who claim they suffered health issues due to exposure ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant.

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing ...

Ein Jahr später sagte er nun, Bayer strebe keine Pharma- und Biotech-Deals an, deren Volumen zum oberen Rand dieser Spanne hin gehe. Priorität habe stattdessen die Senkung der Schuldenlast.

ZURICH (Reuters) - Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.